Liposomal Drug Delivery System - A Concise Review
Sakib M Moinuddin1*, Irfan Sajid2 and Md. Hasanul Arif3
1Guilin Pharmaceutical Co., Ltd., R&D Center, Guangxi, China
2Department of Pharmaceutical Sciences, North South University, Bangladesh
3R&D Department, Orion Pharmaceutical Company Limited, Dhaka, Bangladesh
*Corresponding Author: Sakib M Moinuddin, E-mail: email@example.com
November 15, 2021; Published: December 16, 2021
Liposomes are microscopic self-assembling unilamellar or multilamellar vesicles made up of phospholipid bilayer. Both the hydrophilic and hydrophobic drugs can be attached to the lipid bilayer of liposomes and can show their efficacy in the target cell of the human body. After discovering the liposome by Bangham., et al. and his colleagues, this drug delivery system gained much popularity in every aspect of the pharmaceutical dosage form. Recently, the liposomal drug delivery system has been commercially manufactured and applied in a variety of ailments, including black fungal infection of post-COVID 19, cancer, analgesics, vaccines, and photodynamic therapy, etc. This review tersely described the liposomal formation, classification, characterization, and the overview of marketed drugs.
Keywords: Liposome; Phospholipids; Black Fungus; COVID 19
- Moinuddin S M., et al. “Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: enhanced physical stability, dissolution and pharmacokinetic profile”. International Journal of Pharmaceutics1 (2017): 393-400.
- Moinuddin S M., et al. “Enhanced Physical Stability and Synchronized Release of Febuxostat and Indomethacin in Coamorphous Solids”. AAPS PharmSciTech2 (2020): 1-10.
- Lombardino J G and Lowe J A. “The role of the medicinal chemist in drug discovery—then and now”. Nature Reviews Drug Discovery10 (2004): 853-862.
- Kalepu S., et al. “Liposomal drug delivery system—a comprehensive review”. International Journal of Drug Development and Research 4 (2013): 62-75.
- Mishra H., et al. “A comprehensive review on Liposomes: a novel drug delivery system”. Journal of Drug Delivery and Therapeutics6 (2018): 400-404.
- Bulbake U., et al. “Liposomal formulations in clinical use: an updated review”. Pharmaceutics 2 (2017): 12.
- Nambiar M., et al. “Post-COVID alliance-mucormycosis, a fatal sequel to the pandemic in India”. Saudi Journal of Biological Sciences (2021).
- Divakar P K. “Fungal Taxa Responsible for Mucormycosis/“Black Fungus” among COVID-19 Patients in India”. Journal of Fungi8 (2021): 641.
- Mucormycosis K K P. “A Black Fungus-Post COVID Complications”. Journal of Regenerative Biology and Medicine 4 (2021): 1-8.
- Rahman F I., et al. “Mucormycosis or black fungus infection is a new scare in South Asian countries during the COVID‐19 pandemic: Associated risk factors and preventive measures”. Journal of Medical Virology (2021).
- Akbarzadeh A., et al. “Liposome: classification, preparation, and applications”. Nanoscale Research Letters1 (2013): 1-9.
- Barba A A., et al. “Lipid delivery systems for nucleic-acid-based-drugs: From production to clinical applications”. Pharmaceutics 8 (2019): 360.
- Bangham A. “Lipid bilayers and biomembranes”. Annual Review of Biochemistry1 (1972): 753-776.
- New R and Liposomes, A. “Practical Approach”. Rickwood D., Hames BM, ed. New York: IRL Press, Oxford University Press: 1990.
- Vemuri S and Rhodes C. “Preparation and characterization of liposomes as therapeutic delivery systems: a review”. Pharmaceutica Acta Helvetiae2 (1995): 95-111.
- de Araújo Lopes SC., et al. “Liposomes as carriers of anticancer drugs. Cancer treatment—conventional and innovative approaches” (2013).
- Sharma Vijay K., et al. “Liposomes: present prospective and future challenges”. International Journal of Current Pharmaceutical Review and Research 2 (2010): 6-16.